ACTRN12613000327785
Completed
Phase 3
Evaluation of the clinical pharmacology and pharmacogenomics of ketamine in palliative care patients and chronic pain patients
Andrew Somogyi0 sites50 target enrollmentMarch 25, 2013
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Chronic pain patients
- Sponsor
- Andrew Somogyi
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to be commenced on ketamine based on clinical grounds for refractory cancer or other pain.
- •Fluent in english language.
- •Able to participate in the monitoring of pain and adverse effects
- •Males and females over 18 years
Exclusion Criteria
- •Patients with poor venous access
- •patients in whom significant hypertension or tachycardia would be potentially dangerous
- •Adverse reaction to ketamine in the past
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Pharmaceutico analytical and clinical study of Herbo mineral compound along with Herbal formulation in the management of agni mandya (Thyroid disorder)Health Condition 1: E02- Subclinical iodine-deficiency hypothyroidismCTRI/2023/09/057743ATIONAL INSTITUTE OF AYURVEDA
Not yet recruiting
Phase 1
To see the effect of Taruniyapidikahar lepa in Acne vulgarisCTRI/2023/08/056329ttarakhand Ayurved University
Not yet recruiting
Phase 1
Effect of Arka Taila and Its Cream In VicharchikaHealth Condition 1: L209- Atopic dermatitis, unspecifiedCTRI/2020/08/027269ational Institute of Ayurveda
Not yet recruiting
Phase 2
Study of Gojihwadi kwatha in the management of BronchitisCTRI/2020/09/028118ational Institute of Ayurveda
Recruiting
Phase 2
Vicharchika treatment using Ayurveda medicinesHealth Condition 1: null- VICHARCHIKA/ ECZEMACTRI/2018/02/012006SDM Ayurveda Hospital